Premium
A dipeptidyl peptidase‐4 inhibitor promotes wound healing in normoglycemic mice by modulating keratinocyte activity
Author(s) -
Shih ChunMing,
Huang ChunYao,
Huang ChienYu,
Wang KuoHsien,
Wei PoLi,
Chang YuJia,
Fong TsorngHarn,
Pan JunLiang,
Lee AiWei
Publication year - 2018
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13751
Subject(s) - dipeptidyl peptidase 4 , sitagliptin , wound healing , pharmacology , adiponectin , keratinocyte , diabetes mellitus , dipeptidyl peptidase 4 inhibitor , medicine , keratinocyte growth factor , chemistry , endocrinology , type 2 diabetes , immunology , biochemistry , receptor , growth factor , insulin resistance , in vitro
Dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors are a well‐known and novel class of oral antihyperglycaemic drugs. DPP ‐4 inhibition facilitates ulcer healing in patients with diabetes. However, the actual mechanisms, which are independent of lower blood glucose levels, are still unknown. Therefore, the aim of this study was to analyse the effect of the DPP ‐4 inhibitor sitagliptin on wound healing through a glucose‐independent pathway. In this study, DPP ‐4 inhibitors facilitate keratinocyte differentiation and the proliferation, increase blood flow in the cutaneous of wounds in healthy C57BL/6 mice. Additionally, the administration of the DPP ‐4 inhibitor ameliorates wound healing and enhances adiponectin expression in healthy C57BL/6 mice. Taken together, our results reveal a protective role for the DPP ‐4 inhibitor sitagliptin in wound healing by regulating adiponectin and phospho‐ eNOS levels in keratinocytes. Based on these results, the DPP ‐4 inhibitor may have therapeutic potential for healing wounds through a diabetes‐independent mechanism.